Who are fenofibrate/omega's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Antara (fenofibrate) + Lovaza.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/fenofibrate-omega.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-14 · How we verify

fenofibrate/omega — Competitive Intelligence Brief

fenofibrate/omega (fenofibrate/omega) competitive landscape: 1 comparator, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Fibrate + omega-3 fatty acid combination. Area: Cardiovascular.

marketed Fibrate + omega-3 fatty acid combination PPARα (peroxisome proliferator-activated receptor alpha) Cardiovascular Small molecule Live · refreshed every 30 min

Target snapshot

fenofibrate/omega (fenofibrate/omega) — Gachon University Gil Medical Center. Fenofibrate activates peroxisome proliferator-activated receptor alpha (PPARα) to reduce triglycerides and improve lipid profiles, while omega-3 fatty acids provide additional triglyceride-lowering and anti-inflammatory effects.

Comparator set (1 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
fenofibrate/omega TARGET	fenofibrate/omega	Gachon University Gil Medical Center	marketed	Fibrate + omega-3 fatty acid combination	PPARα (peroxisome proliferator-activated receptor alpha)
Antara (fenofibrate) + Lovaza	Antara (fenofibrate) + Lovaza	GlaxoSmithKline	marketed	Fibrate + Omega-3 fatty acid combination	PPARα (fenofibrate); GPR120, GPR40 (omega-3 fatty acids)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Fibrate + omega-3 fatty acid combination class)

Gachon University Gil Medical Center · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). fenofibrate/omega — Competitive Intelligence Brief. https://druglandscape.com/ci/fenofibrate-omega. Accessed 2026-05-14.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab